These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4650657)

  • 21. Reduction of the oral contraceptive estrogen burden by alternate day estrogen administration.
    Segre EJ; Henzl MR; Giner J; Scheel C; Bessler S
    Contraception; 1975 Aug; 12(2):155-74. PubMed ID: 1139955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bleeding and serum d-norgestrel, estradiol and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception.
    Moore DE; Roy S; Stanczyk FZ; Mishell DR
    Contraception; 1978 Apr; 17(4):315-28. PubMed ID: 648154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eight years of fertility control with norgestrel-ethinyl estradiol (Ovral): an updated clinical review.
    Korba VD; Heil CG
    Fertil Steril; 1975 Oct; 26(10):973-81. PubMed ID: 1183625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Some observations on the changes in capillary resistance in oral contraceptive users.
    Zaki K; Younis MN; Razek SA; Mekkawi TE; Nour H
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):145-51. PubMed ID: 12256025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial clinical studies of intravaginal rings containing norethindrone and norgestrel.
    Mishell DR; lumkin M; Jackanicz T
    Contraception; 1975 Sep; 12(3):253-60. PubMed ID: 1164845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovulation inhibition with sequential therapy. A continuing clinical study of fertility control.
    Suran RR
    Fertil Steril; 1967; 18(5):598-615. PubMed ID: 6037449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent.
    Yuzpe AA; Smith RP; Rademaker AW
    Fertil Steril; 1982 Apr; 37(4):508-13. PubMed ID: 7040117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of injectable norethisterone oenanthate on ovarian hormones in Thai women.
    Werawatgoompa S; Vaivanijkul B; Leepipatpaiboon S; Channiyom K; Virutamasen P; Dusitsin N
    Contraception; 1980 Mar; 21(3):299-309. PubMed ID: 7389353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
    Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
    Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic testing of hypothalamic-pituitary function in abnormalities of ovulation.
    Jones GE; Wentz AC; Rosenwaks Z; Shoemaker J
    Am J Obstet Gynecol; 1977 Dec; 129(7):760-76. PubMed ID: 343592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
    Foegh M; Nicol K; Petersen IB; Schou G
    Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A preliminary pharmacological trial of the monthly injectable contraceptive cycloprovera.
    Fotherby K; Benagiano G; Toppozada HK; Abdel-Rahman A; Navaroli F; Arce B; Ramos-Cordero R; Gual C; Landgren BM; Johannisson E
    Contraception; 1982 Mar; 25(3):261-72. PubMed ID: 6210485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of the metabolic effects of injectable and oral contraceptives.
    Liew DF; Ng CS; Heng SH; Ratnam SS
    Contraception; 1986 Apr; 33(4):385-94. PubMed ID: 2942334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate.
    Coutinho EM; Spinola P; Barbosa I; Gatto M; Tomaz G; Morais K; Yazlle ME; de Souza RN; Pinho Neto JS; Leal Wde B; Leal C; Hippolito SB; Abranches AD
    Contraception; 1997 Mar; 55(3):175-81. PubMed ID: 9115007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
    Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
    Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acceptability of injectable contraceptives in Assiut, Egypt.
    Salem HT; Salah M; Aly MY; Thabet AI; Shaaban MM; Fathalla MF
    Contraception; 1988 Dec; 38(6):697-710. PubMed ID: 2975583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.